Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
AKBA
$11.17
Akebia Therapeutics
($.47)
(4.04%)
AKBA
Earnings Whisper ®
N/A
2nd Quarter June 2020
Consensus: ($0.46)
Revenue: $76.24 Mil
Tuesday
Aug 4
7:00 AM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Tuesday, May 05, 2020
Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
What do you expect when AKBA reports earnings?
Beat
Meet
Miss
Where is AKBA's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$12.62
$12.15
$11.90
$11.43
Support
$11.18
$10.71
$10.46
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Peers
Regeneron Pharmaceuticals
Vertex Pharmaceuticals
BioMarin Pharmaceutical
Johnson & Johnson
InterCept
Zoetis
Mylan
Bristol-Myers Squibb
Ultragenyx Pharmaceutical
Endo International plc
Expectations
›
Akebia Therapeutics
